본문 바로가기
KERD
논문KCI 등재

비소세포폐암종에서 EGFR 단백 발현과 유전자 증폭이제피티닙 치료에 미치는 영향

Protein Expression and Gene Amplification of EpidermalGrowth Factor Receptor in Non-Small Cell Lung Cancer:Correlation with the Response to Gefitinib Therapy

김성환|김치홍|강석진|정지한|심병용|유진영|김훈교|이경지|조덕곤|안명임|조규도
대한병리학회|2008.02|Journal of Pathology and Translational Medicine|제42권 제1호|pp. 1-8

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류병리학

초록

Abstract

Background : Gefitinib is an EGFR tyrosine kinase inhibitor that has shown dramatic effectiveness in a subset of non-small cell lung cancer (NSCLC) patients. We evaluated the response rate to gefitinib, and the significance of the EGFR and HER2/neu status as predictive markers of the tumor response. Methods : The EGFR and HER2/neu protein expressions, as determined by immunohistochemistry (IHC) and gene amplification via chromogenic in situ hybridization (CISH), were analyzed in biopsy specimens from 46 patients with advanced NSCLC. After their failure with the first-line treatment, all the patients had received gefitinib treatment. Results : A partial response (PR) was achieved in 8 patients (17.4%). An EGFR overexpression was detected in 80.4% (37/46) of the tumors, and this was observed exclusively in patients with a PR (100% vs 75.3%, respectively; p=0.076). EGFR gene amplification was present in 47.8% of the tumors (22/46). HER2/neu was overexpressed in 13%(6/46) and it was amplified in 17% (7/46). The overall survival was prolonged in the female patients (p=0.007), and in patients with T1 and T2 disease (p=0.039), adenocarcinoma (p=0.010), a PR (p=0.022), an EGFR IHC+ status (p=0.033), an EGFR IHC+/CISH+ status (p=0.010), or an EGFR+/HER2/neu+ status (p=0.030). On multivariate analysis, gender, T disease and EGFR IHC/CISH remained the significant predictors of survival. Conclusions : Gefitinib showed a modest effect for the patients with chemotherapy-refractory advanced NSCLC. A combination of EGFR IHC and CISH might be important for identifying those patients who are most likely to benefit from gefitinib therapy.

참고문헌 (27)

  1. Jemal A, "Recent trends in lung cancer mortality in the United States", J Natl Cancer Inst, 93, pp.277~283 (2001)
  2. Suzuki S, "Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas", an immunohistochemical and fluorescence in situ hybridization study. Cancer, 103, pp.1265~1273 (2005)
  3. Cappuzzo F, "Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer", J Natl Cancer Inst, 97, pp.643~655 (2005)
  4. Zhang W, "Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation", Clin Cancer Res, 11, pp.600~605 (2005)
  5. Liang K, "The epidermal growth factor receptor mediates radioresistance", Int J Radiat Oncol Biol Phys, 57, pp.246~254 (2003)
  6. Cohen MH, "FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets", Oncologist, 8, pp.303~306 (2003)
  7. Janne PA, "Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘‘Iressa’’) on an expanded access study", Lung Cancer, 44, pp.221~230 (2004)
  8. Miller VA, "Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer", J Clin Oncol, 22, pp.1103~1109 (2004)
  9. Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
  10. Bhargava R, "EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations", Mod Pathol, 18, pp.1027~1033 (2005)
  11. "J Clin Oncol", 2003, 2237~2246
  12. Kris MG, "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer", a randomized trial. JAMA, 290, pp.2149~2158 (2003)
  13. Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
  14. Pao W, "EGF receptor gene mutations are common in lung cancers from ‘‘never smokers’’ and are associated with sensitivity of tumors to gefitinib and erlotinib", Proc Natl Acad Sci USA, 101, pp.13306~13311 (2004)
  15. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
  16. Cappuzzo F, "Should every lung cancer patient be tested for EGFR mutation", Expert Opin Ther Targets, 10, pp.789~791 (2006)
  17. Mitsudomi T, "Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefi- EGFR in NSCLC 7 tinib treatment in patients with non-small-cell lung cancer with postoperative recurrence", J Clin Oncol, 23, pp.2513~2520 (2005)
  18. Toyooka S, "EGFR mutation and response of lung cancer to gefitinib", N Engl J Med, 352, pp.2136~ (2005)
  19. Toschi L, "Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors", Oncologist, 12, pp.211~220 (2007)
  20. Cappuzzo F, "Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive", phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer, 2007, pp.25, 2248~2255
  21. Clark GM, "Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib", J Thorac Oncol, 1, pp.837~846 (2006)
  22. Hirsch FR, "Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer", J Clin Oncol, 24, pp.5034~5042 (2006)
  23. Hirsch FR, "Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib", Ann Oncol, 18, pp.752~760 (2007)
  24. Cappuzzo F, "Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients", J Clin Oncol, 23, pp.5007~5018 (2005)
  25. Gandara DR, "Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition", Clin Cancer Res, 10, pp.S4205~S4209 (2004)
  26. Cappuzzo F, "Gefitinib in pretreated nonsmall- cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC", J Clin Oncol, 21, pp.2658~2663 (2003)
  27. Daniele L, "Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization", chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens, 2007, pp.6, 1223~1229

관련 논문AI추천

비소세포 폐암종의 상피성장인자 수용체 상태와 임상-병리학적 연관성: 단백 발현, 유전자 증폭 및 생존분석최진, 이승구, 장세진대한병리학회 · Journal of Pathology and Translational Medicine2007 · 제41권 제6호Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients김미진, 신경철, 이관호대한병리학회 · Journal of Pathology and Translational Medicine2009 · 제43권 제6호비소세포암종의 Epidermal Growth Factor Receptor발현과 EGFR 돌연변이와의 관계김미진, 석상희대한병리학회 · Journal of Pathology and Translational Medicine2008 · 제42권 제2호진행성 비소세포폐암의 표적치료 및 맞춤항암치료윤탁대한내과학회 · 대한내과학회지2009 · 제77권 제1호면역조직화학적 염색 방법에 따른 상피세포 성장 수용체 단백(EGFR)의 발현정도의 차이 및 EGFR의 발현정도와 EGFR 유전자의 돌연변이와의 상관관계에 대한 고찰김극준, 김상희, 김현용, 석상희, 송호정, 윤인숙, 이은화, 이태종대한임상검사과학회 · 대한임상검사과학회지2007 · 제39권 제3호비소세포 폐암종에서 Thymidylate Synthase의 발현강석진, 김성환, 김수지, 김치홍, 김훈교, 송소향, 심병용, 안명임, 유진영, 조규도, 조덕곤대한병리학회 · Journal of Pathology and Translational Medicine2005 · 제39권 제6호

이 간행물의 다른 논문 (12건)

간세포암종에서 TPEF의 Methylation에 의한 불활성화박지영, 김순영, 김정옥, 김정완, 전소영, 이해암, 손윤경, 강구성, 정운복pp. 9-15Diffuse Large B Cell Lymphoma Shows Distinct MethylationProfiles of the Tumor Suppressor Genes among theNon-Hodgkin’s Lymphomas윤선옥, 김철우, 김영아, 전윤경, 강경훈, 김지은pp. 16-20유방 관상피증식성 병변과 관암종 감별에 있어서의고분자양 CK와 CK5/6 면역염색의 유용성송주연, 윤혜경, 손성희pp. 21-26DNA Copy Number Changes in Thyroid Medullary Carcinomas Determined by Comparative Genomic Hybridization김현정, 송영기, 공경엽, 지관자, 홍석준pp. 27-32Adenocarcinoma Arising from Heterotopic Gastric Mucosain Cervical Esophagus- A Case Report -박승일, 홍영옥, 황정은, 이진혁, 이인철, 조경자pp. 33-36
원문 보기